Clinical trial
An Observational Study of the Use and Safety of Xolair® During Pregnancy
NCT00373061 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00373061 |
|---|---|
| Title | An Observational Study of the Use and Safety of Xolair® During Pregnancy |
| Official title | The Xolair® Pregnancy Registry: An Observational Study of the Use and Safety of Xolair® (Omalizumab) During Pregnancy |
| Acronym | EXPECT |
| Lead sponsor | Genentech, Inc., Industry |
| Collaborators | Novartis Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Asthma |
| Intervention type | Drug |
| Interventions | Xolair® |
| Enrollment | 309 |
| Start date | Oct 20, 2006 |
| Primary completion | Dec 11, 2017 |
| Completion | Jan 5, 2018 |
| First posted | Sep 7, 2006 |
| Last update posted | Feb 14, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: